Psychologists in Junction City, KS Accepting Medicare
6 Psychologists found. Showing 1 - 6
 Shari Kay Lagrange-aulich Psychologist Medicare: Medicare Enrolled Practice Location: 361 Grant Ave, Junction City, KS 66441 Phone: 785-238-4711 |
 Murray Trenton Heikes Psychologist Medicare: Not Enrolled in Medicare Practice Location: 361 Grant Ave, Junction City, KS 66441 Phone: 785-238-4711 |
Richard Johnson Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 7606 Parker St, Fort Riley, Junction City, KS 66442 Phone: 785-240-5814 |
Craig Douglas Lawless, LCP, LMLP Psychologist Medicare: Accepting Medicare Assignments Practice Location: 361 Grant Ave, Junction City, KS 66441 Phone: 785-238-4711 |
Anna-marie Cayley Lauppe Psychologist Medicare: Medicare Enrolled Practice Location: 361 Grant Ave, Junction City, KS 66441 Phone: 785-238-4711 |
Mrs. Janelle Jeffrey, LMSW Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 1013 W 8th St Ste A, Junction City, KS 66441 Phone: 785-210-9619 |
News Archive
Conversations in social media platform can provide new way to communicate about vaccine efficacy
In the early days of COVID-19 vaccine development, a new social media platform provided a place for like-minded people to discuss vaccines, share misinformation and speculate about the motivations for its development.
Research team sheds new light on mercury-containing dental fillings
Amid the on-going controversy over the safety of mercury-containing dental fillings, a University of Saskatchewan research team has shed new light on how the chemical forms of mercury at the surface of fillings change over time.
Three key responses behind food neophobia, the rejection of new foods in both adults and children
Yuk! That short expressive word, the trademark of the fussy eater, is dreaded by thousands of parents.
ImmunoCellular to expand ICT-107 Phase IIb trial on GBM
ImmunoCellular Therapeutics, Ltd., a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it will expand its current Phase IIb trial of ICT-107 from 102 to up to 123 patients with glioblastoma multiforme (GBM) and who are HLA-A1/A2 positive.
› Verified 3 days ago
Counselors
Clinical Social Workers
Occupational Therapists
Pharmacists
Dentists
Psychologists